Tirzepatide shows promising hepatic effects in ongoing MASLD trials, and semaglutide has demonstrated modest liver fat reduction, but neither approaches the retatrutide benchmark
After years of hiding myself, I wanted to wear dresses and bathing suits but was confronted by the crepey, loose skin that enveloped my new body
Novo Nordisk, maker of Ozempic and Wegovy, lists the telehealth company LifeMD on its website as a provider that offers legitimate medicine sourcing and patient support for people seeking GLP-1 drugs
In particular with GLP-1s, compounding has filled an important gap that FDA should consider
How Policy Shifts Could Expand Obesity Drug Coverage A major barrier preventing widespread access to GLP-1 medications is the lack of insurance coverage, especially for weight loss
Average weight loss is usually 1525% of someones total body weight 3 after about one year (compared with about 23% when taking a placebo)